IPO Analysis

Himalaya Nutravedics IPO Analysis: Should You Apply? GMP, Review & Details

TF

TopFund Research

Published · Updated

AI-assisted

TL;DR

  • Price band: ₹100.0–₹106.0 per share, lot size 1200.
  • Opens 22 Sep, closes 24 Sep 2026.
  • GMP not yet available for this IPO.
  • Expected listing: 29 Sep 2026 on BSE SME.
  • Full company analysis, risk factors and FAQs below — this is educational content, not a buy/subscribe recommendation.

Himalaya Nutravedics is a SME IPO in the Other Food Products sector. The issue price band is ₹100.0–₹106.0 per share. Issue size is ₹26.5 crore.

Himalaya Nutravedics IPO — Key Details

FieldValue
Price Band₹100.0–₹106.0
Lot Size1200
Issue Size₹26.5 Cr
GMPNot yet available
Open Date22 Sep 2026
Close Date24 Sep 2026
Listing Date29 Sep 2026

Company Overview

Himalaya Nutravedics India Ltd is engaged in the manufacturing, marketing, and distribution of Ayurvedic and nutraceutical formulations in India. The company operates a hybrid business model that includes both its own branded products and third-party contract manufacturing. Its diverse product range includes classical Ayurvedic formulations, proprietary Ayurvedic products, and nutraceutical supplements available in various dosage forms. The company has an integrated manufacturing facility in Hyderabad and distributes its products across multiple states in India, focusing on wellness and therapeutic segments.

Financial Performance

Total income was ₹14.43 Cr in the year ending 31 Mar 2024, rising to ₹21.00 Cr by 31 Mar 2025, and further increasing to ₹43.12 Cr by 31 Mar 2026. This shows a strong growth trend in revenue over the periods. Profit after tax was ₹0.43 Cr for the year ending 31 Mar 2024, increasing to ₹2.23 Cr by 31 Mar 2025, and further rising to ₹7.39 Cr by 31 Mar 2026. This indicates a significant upward trend in profitability.

Objects of the Issue

The Company proposes to utilise the Net Proceeds from the Issue towards the following objects: Funding Working Capital Requirements (₹13.75 Cr), Business Development and Digital Marketing Activities (₹7.50 Cr), and General Corporate Purposes (Total ₹21.25 Cr).

Strengths & Weaknesses

Strengths

Himalaya Nutravedics has an integrated multi-dosage manufacturing capability, doctor acceptance supported by product performance, long-standing relationships with suppliers and customers, and broad therapeutic coverage across the Ayurvedic and nutraceutical segments.

Understanding Grey Market Premium (GMP)

The Grey Market Premium (GMP) refers to the unofficial trading of shares before they are listed on the stock exchange. It indicates the expected listing price of the IPO shares based on demand and supply in the grey market. A higher GMP suggests strong demand, while a lower or negative GMP may indicate weak demand.

Subscription Status

The IPO received a total subscription of 2.33 times as of 24th Sep 2026. The breakdown shows strong interest from Non-Institutional Investors (3.58 times) and Retail Investors (2.56 times), while Qualified Institutional Buyers subscribed at 1.0 times.

Peer Comparison

  • Himalaya Nutravedics has a P/E ratio of 9.04.
  • Sandu Pharmaceuticals Ltd. has a P/E ratio of 20.62.
  • Jeena Sikho Lifecare Ltd. has a P/E ratio of 26.75.

IPO Timeline

The IPO opens for subscription on 22nd September 2026 and closes on 24th September 2026. Allotment of shares will be done on 25th September 2026, with the listing date set for 29th September 2026.

Should You Apply for Himalaya Nutravedics IPO?

Investors comfortable with short-term volatility and a long-term horizon typically weigh IPOs like this against their investment goals and risk tolerance. It's important to consider the company's growth potential and market position.

Investors who prefer stable returns and are risk-averse may want to avoid IPOs like this, which can be subject to high volatility and market fluctuations.

This is general risk-profile education, not a personal recommendation to apply or avoid this specific IPO — TopFund is not a SEBI-registered investment adviser.

Listing Day Risks

Listing gains refer to the potential profit an investor might make on the first day of trading after an IPO. However, these gains are not guaranteed and can be influenced by market conditions and investor sentiment. It's important to understand that investing in IPOs carries risks, and prices can fluctuate significantly after listing.

Trending Searches

Himalaya Nutravedics IPO GMP todayHimalaya Nutravedics IPO reviewHimalaya Nutravedics IPO allotment dateHimalaya Nutravedics IPO listing dateshould I apply Himalaya Nutravedics IPOHimalaya Nutravedics IPO price bandHimalaya Nutravedics IPO subscription status

Disclaimer: This is educational content, not investment advice. GMP is an unofficial grey-market indicator, unregulated and never guaranteed. TopFund is not a SEBI-registered investment adviser — please do your own research or consult a qualified adviser before applying to any IPO.

Frequently Asked Questions

What is the lot size for this IPO?

The lot size for Himalaya Nutravedics IPO is 1200 shares.

What is the minimum investment required?

The minimum investment required for this IPO is ₹254,400.

What is the price band for the IPO?

The price band for the Himalaya Nutravedics IPO is ₹100.0 to ₹106.0.

When is the listing date for the IPO?

The listing date for the Himalaya Nutravedics IPO is 29th September 2026.

What does GMP mean?

GMP stands for Grey Market Premium, which indicates the expected listing price of the IPO shares based on demand in the unofficial market.

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

No comments yet — start the discussion.

TopFund Weekly Digest

Every Sunday — live IPO GMP, top mutual funds & market news. Free, no spam.

No spam · Unsubscribe anytime · 6 readers